Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival-Reference-Cited by-同舟云学术

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival

Published:2016-07 Issue:7 Volume:16 Page:379-386
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Dhakal Binod,D'Souza Anita,Martens Michael,Kapke Jonathan,Harrington Alexandra M.,Pasquini Marcelo,Saber Wael,Drobyski William R.,Zhang Mei Jie,Hamadani Mehdi,Hari Parameswaran N.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference42 articles.

1. Role of allogeneic stem cell transplantation in multiple myeloma;Kumar;Curr Hematol Malig Rep,2008

2. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma;Wang;Blood,2013

3. Elotuzumab therapy for relapsed or refractory multiple myeloma;Lonial;N Engl J Med,2015

4. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation;Libura;Bone Marrow Transplant,1999

5. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma;Lokhorst;J Clin Oncol,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Refractory Multiple Myeloma;2024-01-24

3. A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation;American Journal of Case Reports;2022-03-18

4. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse;Frontiers in Oncology;2022-02-02

5. Allogeneic Stem Cell Transplantation in Multiple Myeloma;Cancers;2021-12-23